Skip to main content
MaaT Pharma logo

MaaT Pharma — Investor Relations & Filings

Ticker · MAAT ISIN · FR0012634822 LEI · 969500CQQB6XUNW6CN97 PA Professional, scientific and technical activities
Open in API
Filings indexed 347 across all filing types
Latest filing 2023-05-26 AGM Information
Country FR France
Listing PA MAAT

About MaaT Pharma

https://www.maatpharma.com/

MaaT Pharma is a clinical-stage biotechnology company specializing in the development of microbiome-based therapeutics. The company's primary focus is on oncology, aiming to improve survival outcomes for cancer patients by modulating the immune system through the gut microbiome. It develops Microbiome Ecosystem Therapies (MET) designed to restore gut microbiome symbiosis. The company's pipeline includes product candidates for treating complications in patients with blood cancers and solid tumors, with its lead candidate, MaaT013, in late-stage development for acute Graft-versus-Host Disease (aGvHD). MaaT Pharma utilizes an AI-powered platform for drug development and has its own cGMP manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Terms of availability of the preparatory documents for the GM
AGM Information Classification · 98% confidence The document explicitly announces a 'combined Annual General Meeting (AGM) on June 19, 2023' and details the availability of the 'preparatory documents' and voting procedures for shareholders. It mentions the agenda, proposed resolutions, and how shareholders can access the required materials (Article R. 22-10-23 of the French Commercial Code). Since the core purpose of this text is to inform shareholders about the upcoming AGM and the associated materials required for that meeting, the most appropriate classification is AGM Information (AGM-R). Although it mentions the availability of documents, the primary focus is the meeting itself, making AGM-R more specific than RPA or RNS.
2023-05-26 English
Information financière trimestrielle / Information financière du premier trimestre
Earnings Release Classification · 100% confidence The document is titled "MaaT Pharma publie sa position de trésorerie et son chiffre d'affaires pour le premier trimestre 2023" (MaaT Pharma publishes its cash position and revenue for the first quarter of 2023). It explicitly reports key financial metrics (cash position: 40.7M€, revenue: 0.7M€) for a specific interim period (Q1 2023). This content aligns perfectly with the definition of an Interim / Quarterly Report (IR), which covers comprehensive financial reporting for a period shorter than a year. Although it contains highlights, the level of detail regarding cash flow changes and operational updates suggests it is more than just a brief Earnings Release (ER). It is not a full Annual Report (10-K) as it covers only Q1. It is not a Report Publication Announcement (RPA) because it contains the actual financial data, not just an announcement that a report is available. Therefore, the most appropriate classification is IR. Q1 2023
2023-05-09 French
Quarterly financial reporting / First quarter financial report
Earnings Release Classification · 100% confidence The document is a press release dated May 9th, 2023, reporting the company's 'Cash and Revenues for the First Quarter of 2023'. It explicitly states key financial metrics (cash position as of March 31, 2023, and Q1 2023 revenues) and provides operational highlights for the quarter. This content structure—announcing period-specific financial results immediately following the period's end—is characteristic of an Earnings Release (ER). It is not a comprehensive Annual Report (10-K) or a detailed Interim/Quarterly Report (IR), as it focuses on highlights and key figures rather than full financial statements, and it is not a transcript (CT) or a presentation (IP). The document also lists upcoming financial communications, confirming its role as a periodic results announcement. Q1 2023
2023-05-09 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers - AMF) and provides a table detailing the total number of shares and voting rights as of April 30, 2023. This type of mandatory periodic disclosure regarding the share capital structure and voting rights is a specific regulatory filing, but it does not fit perfectly into the standard US SEC forms (like 10-K, ER, MRQ). Among the provided definitions, the closest fit for a mandatory, periodic, non-financial-result-focused regulatory update that deals with share structure is often categorized under general regulatory announcements or specific capital structure changes. Since it is a mandatory disclosure about the total number of shares and voting rights, it relates closely to capital structure, but it is not a financing event (CAP) or a share repurchase (POS). It is a routine disclosure of the current share count. Given the options, this specific type of monthly capital/voting rights disclosure is best classified as a general Regulatory Filing (RNS) or potentially related to Share Issue/Capital Change (SHA) if it were a change, but since it's a routine update, RNS is the most appropriate general regulatory bucket, although it is very close to the concept of 'Share Issue/Capital Change' (SHA) if we interpret SHA broadly to include reporting on the current state of capital. However, looking closely at the definitions, there is no specific code for 'Share Capital Disclosure'. Since it is a formal, mandated regulatory update that doesn't fit the other specific financial or event-driven codes, RNS (Regulatory Filings - general regulatory announcements and fallback category) is the most suitable classification.
2023-05-03 French
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Regulatory Filings Classification · 95% confidence The document is titled "Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital" and explicitly references French regulatory articles (AMF General Regulations, French Commercial Code) requiring the publication of this data monthly. It provides a table detailing the total number of shares and voting rights as of April 30, 2023. This specific type of mandatory monthly disclosure regarding share capital and voting rights does not fit neatly into the primary categories like 10-K, ER, or IR. It is a specific regulatory disclosure concerning share structure. Among the provided codes, 'RNS' (Regulatory Filings - General regulatory announcements and fallback category for miscellaneous filings) is the most appropriate fit for this mandatory, periodic, but non-financial results-focused regulatory update that doesn't match other specific types like DIRS or DIV. It is not a general announcement of a report (RPA), but the report itself.
2023-05-03 English
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is a press release dated April 24, 2023, announcing that the U.S. FDA has lifted a clinical hold on an Investigational New Drug (IND) application for MaaT013. This announcement details regulatory progress, clinical trial status (Phase 3), and future strategic outlook regarding U.S. market entry. This type of communication, focusing on significant regulatory milestones and clinical development updates, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific, material announcement about regulatory clearance and clinical progress, it fits best under the 'Earnings Release' category if it were tied to a reporting period, or more generally as a significant corporate update. Given the options, it is a material announcement that is not a full report (like 10-K or IR), nor a management discussion (MDA), nor a specific financing/dividend event. It is a major corporate development announcement. In the context of financial filings, major non-financial operational news like FDA clearance often falls under the broader 'Regulatory Filings' (RNS) or sometimes an 'Earnings Release' (ER) if issued around earnings time, but since it's purely regulatory/clinical news, RNS is the most appropriate fallback for significant, non-standard announcements. However, many companies issue these updates as standalone press releases that function similarly to an ER in terms of market impact. Given the content is a major operational/regulatory update, and not a standard financial summary, RNS is the safest classification, though ER is also plausible if this was part of a quarterly cycle. I will classify it as RNS as it is a specific regulatory/clinical update announcement.
2023-04-24 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.